A case report of semaglutide induced sarcopenia: causes of fatigue in older adults.

Mohamad AA

Korean journal of family medicine14 Apr 2025Cited by 3 (Europe PMC)

PMID40223309PMCIDPMC12301675DOI10.4082/kjfm.25.0008PepBankPUB-40223309

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study5

4 results from studies that gave the peptide. 4 results from people.

01HumanCase report or seriesSafety outcome
A 74-year-old man with type 2 diabetes had progressive fatigue over 2 years, attributed by the authors to semaglutide.
In plain wordsOne 74-year-old man with diabetes had growing tiredness over 2 years, which the authors link to semaglutide.
Peptide
Semaglutide
Outcome
IncreaseProgressive fatigue
Study
n = 1
Outcome group
Exercise and physical function · Whole body
Studied dose
Dose not stated
Source sentences
Summary
A 74-year-old male patient with type 2 diabetes and dyslipidemia presented with progressive fatigue over 2 years.
1 context sentence(design, population, supporting numbers)
Summary · context
This case highlights the potential contribution of semaglutide to muscle mass loss and subsequent fatigue, particularly among older adults.
Report a problemFND-4022330901
02HumanCase report or seriesSafety outcome
A 74-year-old man with type 2 diabetes had a significant decline in walking endurance and speed with no other obvious cause.
In plain wordsOne 74-year-old man with diabetes walked less far and more slowly, with no other obvious cause found.
Peptide
Semaglutide
Outcome
DecreaseWalking endurance and speed
Study
n = 1
Outcome group
Exercise and physical function · Musculoskeletal
Studied dose
Dose not stated
Source sentences
Summary
He experienced a significant decline in walking endurance and speed despite the absence of joint pain or other obvious causes.
1 context sentence(design, population, supporting numbers)
Summary · context
A 74-year-old male patient with type 2 diabetes and dyslipidemia presented with progressive fatigue over 2 years.
Report a problemFND-4022330902
03HumanCase report or seriesEfficacy outcome
A 74-year-old man with type 2 diabetes lost 8 kg after starting semaglutide.
In plain wordsOne 74-year-old man with diabetes lost 8 kg after starting semaglutide.
Peptide
Semaglutide
Outcome
DecreaseBody weight after starting semaglutide
Study
n = 1
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated
Measurements
Weight loss
8 kg
after starting semaglutide
Source sentences
Summary
Further investigation revealed a weight loss of 8 kg after starting semaglutide treatment for diabetes.
1 context sentence(design, population, supporting numbers)
Summary · context
A 74-year-old male patient with type 2 diabetes and dyslipidemia presented with progressive fatigue over 2 years.
Report a problemFND-4022330903
04HumanCase report or seriesSafety outcome
A 74-year-old man with type 2 diabetes who took semaglutide had reduced muscle bulk and strength on examination.
In plain wordsOne 74-year-old man with diabetes who took semaglutide had less muscle bulk and strength on examination.
Peptide
Semaglutide
Outcome
DecreaseMuscle bulk and strength
Study
n = 1
Outcome group
Body composition · Musculoskeletal
Studied dose
Dose not stated
Source sentences
Summary
Physical examinations revealed reduced muscle bulk and strength.
2 context sentences(design, population, supporting numbers)
Summary · context
Further investigation revealed a weight loss of 8 kg after starting semaglutide treatment for diabetes.
Summary · context
A 74-year-old male patient with type 2 diabetes and dyslipidemia presented with progressive fatigue over 2 years.
Report a problemFND-4022330904

Studies that did not test the peptide alone1

In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Semaglutide.

05HumanNot a test of Semaglutide aloneCase report or seriesEfficacy outcome
In a 74-year-old man with type 2 diabetes, fatigue improved after the semaglutide dose was reduced together with a tailored muscle-strengthening exercise program.
In plain wordsOne 74-year-old man with diabetes felt less tired after his semaglutide dose was cut and he started an exercise program.
Peptide
Semaglutide
Outcome
DecreaseFatigue after dose reduction and exercise program
Study
n = 1
Outcome group
Exercise and physical function · Whole body
Source sentences
Summary
The patient's fatigue improved after reducing the semaglutide dose and implementing a tailored exercise program that focused on muscle strengthening.
1 context sentence(design, population, supporting numbers)
Summary · context
A 74-year-old male patient with type 2 diabetes and dyslipidemia presented with progressive fatigue over 2 years.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4022330905

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 00:04 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.